Lung Cancer Clinical Trials in Boston

Showing 341-360 of 553 trials

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

NCT02857270

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

Advanced CancerMetastatic MelanomaMetastatic Non-small Cell Lung Cancer+1 more

Eli Lilly and Company210 participantsStarted Sep 2016

Washington D.C., District of Columbia, United States • Sarasota, Florida, United States • Boston, Massachusetts, United States +10 more locations

UNKNOWNNA< 1 mile

The Transitions Project: Efficacy Trial

NCT05087251

The aim of this study is to evaluate the efficacy of a brief psychoeducational intervention to improve quality of life in patients with lung cancer who are transitioning from active treatment to surveillance.

Lung Cancer

Massachusetts General Hospital100 participantsStarted Sep 2021

Boston, Massachusetts, United States • Boston, Massachusetts, United States

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

The Transitions Project: Efficacy Trial

Lung Cancer Trials in Other Cities

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Pilot Study of Biopsy Scanner for Evaluation of Bronchoscopic Small Biopsy Specimens to Determine Adequacy

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Safety Study of MGA271 in Refractory Cancer

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

A Study of LY3023414 in Participants With Advanced Cancer

Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Other Conditions in Boston